ArticleInfection and drug resistance2026
Ventilation-Associated Differences in Lower Airway Microbial Signatures and Peripheral Blood Transcriptome Among Critically Ill COVID-19 Patients.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Invasive mechanical ventilation (IMV) is a critical intervention for severe respiratory failure and has been widely used in the clinical management of COVID-19 patients. The relationship between such microbiota changes and the host transcriptome in IMV patients remains poorly documented. Methods: We prospectively enrolled 69 critically ill COVID-19 patients, among whom 41 received IMV. Correlation analyses were conducted to investigate the relationship between the lung microbiome and host immune status in IMV COVID-19 patients. Results: Compared to the Non-mechanical ventilation (NMV) group, patients in the IMV group exhibited significantly reduced alpha diversity, while no significant difference was observed in beta diversity. The abundance of Streptococcus genus was significantly higher in the NMV group, primarily dominated by Streptococcus oralis and Streptococcus mitis. Transcriptomic enrichment analysis revealed significant upregulation of inflammation-related pathways in the IMV group, including "positive regulation of inflammatory response" and "cellular response to interleukin-1". The decreased relative abundance of Streptococcus genus in the IMV group showed significant correlations with upregulation of genes including CXCL8, PLAU, SELENOK, SDC4, RPL17, RPS23, TOMM7, and PLK3. These upregulated genes promoted the recruitment of immune cells to inflammatory sites through activation of pathways including chemotaxis, leukocyte migration, and leukocyte cell-cell adhesion, ultimately triggering a robust innate immune response. Conclusion: IMV COVID-19 ARDS patients demonstrated significantly reduced pulmonary microbial diversity, with a marked decrease in the abundance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.